Clinical Trial Update: The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a BCMA/CD19 dual-targeted CAR-T cell therapy for autoimmune kidney diseases, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Igg4-related Disease
• Lupus Nephritis
• Membranous Nephropathy

Drugs mentioned

• BCMA/CD19 dual-targeted CAR-T cell therapy

Snippet

Sponsor: Nanjing University School of Medicine | Conditions: Lupus Nephritis, ANCA-associated Vasculitis | Phase 1 | Status: RECRUITING